Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Landiolol Microcirculatory Effects in Septic Shock
NCT04931225Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of landiolol in septic shock (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Rate of decrease in heart rate (HR) on microcirculatory vascular reactivity at 24 hours. Started Jul 2022; status: recruiting.
02
Drugs
landiolol
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT04931225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931225.